期刊文献+

霉酚酸的药代动力学与药效学研究进展 被引量:3

Research progress of the pharmacokinetics and pharmacodynamics of mycophenolic acid
原文传递
导出
摘要 霉酚酸是一种选择性、非竞争性、可逆的次黄嘌呤单核苷酸脱氢酶(IMPDH)抑制药,其作为免疫抑制剂已被国内外广泛应用于移植器官急性排异反应以及自身免疫性疾病的预防和治疗。本文对霉酚酸的药代动力学、药效学及其相关性研究等作一综述。 Mycophenolic acid( MPA) is the reversible and noncompetitive inhibitor of inosine monophosphate dehydrogenase( IMPDH). It is widely used to prevent rejection after organ transplantation and treat autoimmune diseases,as an immunosuppressive agent. This article reviews the pharmacokinetics( PK),pharmacodynamics( PD) and PK / PD correlation studies of MPA recently published.
作者 陆佳倩 陈冰
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第6期573-576,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(81473275) 上海市自然科学基金资助项目(12ZR1418900)
关键词 霉酚酸 药代动力学 药效学 次黄嘌呤单核苷酸脱氢酶 相关性 mycophenolic acid pharmacokinetics pharmacodynamics inosine monophosphate dehydrogenase correlation
  • 相关文献

参考文献2

二级参考文献12

  • 1Srinivas TR, Kaplan B, Meier - Kriesche HU. Myeophenolate mofetil in solid-organ transplantation [ J ]. Expert Opin Pharmacother, 2003 ; 4 : 2325 - 2345.
  • 2Chen H, Peng C, Yu Z, et al. Pharmacnkinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients [ J]. Clin Pharmacokinet, 2007 ; 46 : 175 - 185.
  • 3Milln O, Brunet M, Martorell J, et al. Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir [ J ]. Clin Pharmacokinet, 2005 ; 44 : 525 - 538.
  • 4Chen H, Gu Z, Chen B, et al. Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation [ J]. Clin Ther, 2008 ; 30:2387 - 2401.
  • 5Budde K, Glander P, Kramer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes [ J]. Transplantation, 2007 ; 83 : 417 - 424.
  • 6Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid : report of a roundtable discussion [ J ]. Ther Drug Monit, 2001 ; 23 : 305 - 315.
  • 7Millan O, Oppenheimer F, Brunet M, et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach [ J ]. Clin Chem, 2000; 46:1376 - 1383.
  • 8Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil [ J ]. Transplantation, 2006; 81:541 -546.
  • 9Okamoto M,Wakabayashi Y,Higuchi A. Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients[J].{H}Transplantation Proceedings,2005,(02):859-860.
  • 10任斌,李敏薇,唐蕾,王长希,李瑞明,容颖慈,陈坚平,黎曙霞.高效液相色谱法快速测定霉酚酸血药浓度[J].中国医院药学杂志,2008,28(5):407-408. 被引量:7

共引文献6

同被引文献15

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部